Human Genome Epidemiology Literature Finder
|
Records 1 - 11 (of 11 Records) |
| Query Trace: Nausea and DPYD[original query] |
|---|
| DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Medical oncology (Northwood, London, England) 2007 24 (2): 251-8. Zhang Hong, Li You-ming, Zhang Hao, Jin |
| [The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma]. Zhonghua nei ke za zhi 2007 Feb 46 (2): 103-6. Zhang Hong, Li You-ming, Yu Chao-hui, Wang Sheng-qi, Ji Feng, Chen Chun-xi |
| Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer chemotherapy and pharmacology 2013 Feb 71 (2): 361-70. Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl St, Froehlich T K, Largiader C R, Joerger |
| [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L |
| Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clinical biochemistry 2016 Jul . Galarza Andrés Fernando Andrade, Linden Rafael, Antunes Marina Venzon, Hahn Roberta Zilles, Raymundo Suziane, da Silva Anne Caroline Cezimbra, Staggemeier Rodrigo, Spilki Fernando Rosado, Schwartsmann Gilber |
| Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. European journal of cancer (Oxford, England : 1990) 2018 8 102 31-39. Madi Ayman, Fisher David, Maughan Timothy S, Colley James P, Meade Angela M, Maynard Julie, Humphreys Vikki, Wasan Harpreet, Adams Richard A, Idziaszczyk Shelley, Harris Rebecca, Kaplan Richard S, Cheadle Jeremy |
| Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 2018 Feb 9 (10): 9114-9136. Tecza Karolina, Pamula-Pilat Jolanta, Lanuszewska Joanna, Butkiewicz Dorota, Grzybowska E |
| The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population. Avicenna journal of medical biotechnology 0 12 (3): 157-164. Abbasian Mohammad Hadi, Ansarinejad Nafiseh, Abbasi Bahareh, Iravani Masoud, Ramim Tayeb, Hamedi Fahime, Ardekani Ali |
| Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC cancer 2020 6 20 (1): 560. Negarandeh Reza, Salehifar Ebrahim, Saghafi Fatemeh, Jalali Hossein, Janbabaei Ghasem, Abdhaghighi Mohammad Javad, Nosrati Anahi |
| Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. The pharmacogenomics journal 2021 Jan . Vivaldi Caterina, Crucitta Stefania, Catanese Silvia, Cucchiara Federico, Arrigoni Elena, Pecora Irene, Rofi Eleonora, Fornaro Lorenzo, Salani Francesca, Massa Valentina, Vasile Enrico, Morganti Riccardo, Danesi Romano, Del Re Marz |
| Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population. Cancer chemotherapy and pharmacology 2022 9 90 (5): 389-397. Salmani Mohammad, Ghaderi Bayazid, Fotoohi Alan, Omid-Shafa'at Ramtin, Vahabzadeh Zakaria, Fotouhi Omid, Abdi Mohamm |
- Page last reviewed:Feb 1, 2024
- Content source: